

**REMARKS**

Claims 25, 26, and 28-30 are pending in this application. Claims 25, 26, and 28 stand rejected. Claims 29 and 30 are allowed. Applicants cancel claims 25, 26 and 28 herein.

**Specification**

The Examiner requires Applicants to update priority information by providing US patent numbers. Applicants amend the specification herein to include updated priority information.


**35 U.S.C. § 112, first paragraph**

Claims 25-26, and 28 stand rejected under 35 U.S.C., § 112, first paragraph for allegedly not being enabling. Applicants cancel claims 25, 26, and 28, thus, rendering rejection of these claims moot.

Applicants reserve the right to prosecute, in one or more patent applications, the claims to non-elected inventions, the claims as originally filed, and any other claims supported by the specification. Applicants have concurrently filed a continuation application to this application. Accordingly, favorable reconsideration and allowance of the pending claims is earnestly solicited.

If it would expedite the prosecution of this application, the Examiner is invited to confer with Applicants' undersigned attorney.

Respectfully submitted,



Andrea V. Lockenour  
Attorney for Applicants  
Registration No. 51,962

GlaxoSmithKline  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-7568  
Facsimile (610) 270-5090  
n:\avl\patapps\lp-pla2\p30693c4x1c1\roaaf.doc